Pemafibrate

(Synonyms: (R)-K-13675; K-877)
10 Cited Publications
Customer Review

Based on 10 publication(s) in Google Scholar

Pemafibrate ((R)-K-13675; K-877) is an orally active and selective PPARα agonist. Pemafibrate activates PPARα/RXR-driven genes involved in lipid and glucose metabolism and fatty acid oxidation, restores hepatic NAD+/NADH redox balance, lowers serum and hepatic triglycerides, and prevents steatosis and inflammation. Pemafibrate increases hepatic expression of CPT2, VLCAD, ACOX1, PPARα, and CPT1A, suppresses endothelial/macrophage inflammation and NF-κB, promotes cholesterol efflux to HDL, and reduces atherosclerotic lesions. Pemafibrate inhibits oxidative stress and mitochondrial apoptosis, reduces de novo triglyceride/cholesterol synthesis, increases β-oxidation, suppresses VLDL secretion, accelerates LPL-mediated triglyceride clearance, and induces FGF21. Pemafibrate can be used in research on metabolism-related diseases, such as atherogenic dyslipidemia, diabetic myocardial ischemia-reperfusion injury, and fatty liver disease.

For research use only. We do not sell to patients.

  • Purity : 99.81%
  • CAS No.: 848259-27-8
  • Formula: C28H30N2O6
  • Molecular Weight:490.55
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00